{
    "nctId": "NCT01155063",
    "briefTitle": "Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients",
    "officialTitle": "A Non-Interventional Observational Study Evaluating The Effects Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy On Safety In Postmenopausal And Hormone Receptors Positive Early Breast Cancer Patients",
    "overallStatus": "TERMINATED",
    "conditions": "Early Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 89,
    "primaryOutcomeMeasure": "Number of Participants With Adverse Events (AEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal females.\n* Patients who have had surgical treatment for histological confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.\n* Patients who are disease-free after 2 or 3 years of adjuvant tamoxifen treatment.\n* Patients whose tumour was estrogen receptor positive (ER+).\n* Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.\n\nExclusion Criteria:\n\n* Patients for whom Aromasin\u00ae treatment is contraindicated (see SPC).\n* Presence of metastasis or a contra lateral tumour.\n* Other adjuvant endocrine therapy.\n* Another concomitant antineoplastic treatment.\n* Participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}